bucindolol
Sign in to saveBucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and intrinsic sympathomimetic activity in some model systems but not in human hearts. It was under review by the FDA in the United States for the treatment of heart failure in 2009, but was rejected due to issues pertaining to integrity of data submitted.
Research
201 papers- Bucindolol hydrochloride in atrial fibrillation and concomitant heart failure.Expert review of cardiovascular therapy · 2015
- Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure.Current heart failure reports · 2017
- Bucindolol.The American journal of cardiology · 1985
- Pharmacokinetic drug evaluation of bucindolol for the treatment of atrial fibrillation in heart failure patients.Expert opinion on drug metabolism & toxicology · 2017
- Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF Trial.JACC. Heart failure · 2019
via PubMed
Wikidata facts
- Mass
- 363.195
Show 2 more facts
- chemical formula
- C₂₂H₂₅N₃O₂
- canonical SMILES
- CC(C)(CC1=CNC2=CC=CC=C21)NCC(COC3=CC=CC=C3C#N)O
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
3 sectionsContents
- Synthesis
- See also
- References
Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and intrinsic sympathomimetic activity in some model systems but not in human hearts. It was under review by the FDA in the United States for the treatment of heart failure in 2009, but was rejected due to issues pertaining to integrity of data submitted.
==Synthesis== 500px|class=skin-invert-image
Excerpted from Wikipedia’s “bucindolol” article, available under the CC BY-SA 4.0 licence.
Available in 7 languages
via Wikidata sitelinks · CC0